Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
スポンサーリンク
概要
- 論文の詳細を見る
- 2009-11-15
著者
-
Pierce Sherry
Department Of Leukemia Unit 428 The University Of Texas M. D. Anderson Cancer Center
-
Cortes Jorge
Department Of Leukemia Unit 428 The University Of Texas M. D. Anderson Cancer Center
-
SEVER Matjaz
Department of Leukemia, The University of Texas MD Anderson Cancer Center
-
KANTARJIAN Hagop
Department of Leukemia, The University of Texas MD Anderson Cancer Center
-
JAIN Nitin
Department of Leukemia, The University of Texas MD Anderson Cancer Center
-
ESTROV Zeev
Department of Leukemia, The University of Texas MD Anderson Cancer Center
-
VERSTOVSEK Srdan
Department of Leukemia, The University of Texas MD Anderson Cancer Center
-
Jain Nitin
Department Of Leukemia The University Of Texas Md Anderson Cancer Center
-
Sever Matjaz
Department Of Leukemia M.d. Anderson Cancer Center
-
Estrov Zeev
Department Of Leukemia Unit 428 The University Of Texas M. D. Anderson Cancer Center
-
Estrov Zeev
Department Of Leukemia The University Of Texas M. D. Anderson Cancer Center
-
Verstovsek Srdan
Department Of Leukemia M.d. Anderson Cancer Center
-
Kantarjian Hagop
Department Of Leukemia Unit 428 The University Of Texas M. D. Anderson Cancer Center
-
Kantarjian Hagop
Department Of Leukemia The University Of Texas M.d. Anderson Cancer Center
-
Cortes Jorge
Department Of Leukemia M.d. Anderson Cancer Center
-
Kantarjian Hagop
Department Of Leukemia M.d. Anderson Cancer Center
-
Kantarjian Hagop
Department Of Leukemia The University Of Texas Md Anderson Cancer Center
関連論文
- Incidence of extramedullary disease in patients with acute promyelocytic leukemia : a single-institution experience
- Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
- Imatinib mesylate therapy for polycythemia vera : final result of a phase II study initiated in 2001
- The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2^ mutation
- Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406
- Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells
- New Strategies in Chronic Myeloid Leukemia
- Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
- Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia